Catalent logo

Catalent Stock

StockStock
ISIN: US1488061029
Ticker: CTLT
US1488061029
CTLT

Price

Frequently asked questions

What is Catalent's market capitalization?

The market capitalization of Catalent is $10.79B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Catalent?

Catalent's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.269. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Catalent's stock?

Currently, 9 analysts cover Catalent's stock, with a consensus target price of $57.89. Analyst ratings provide insights into the stock's expected performance.

What is Catalent's revenue over the trailing twelve months?

Over the trailing twelve months, Catalent reported a revenue of $4.42B.

What is the EBITDA for Catalent?

Catalent's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $658.00M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Catalent?

Catalent has a free cash flow of $99.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Catalent's stock?

The 5-year beta for Catalent is 1.14. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Catalent have, and what sector and industry does it belong to?

Catalent employs approximately 16,900 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Catalent's shares?

The free float of Catalent is 178.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$10.79B

5Y beta

 
1.14

EPS (TTM)

 
-$2.269

Free Float

 
178.50M

Revenue (TTM)

 
$4.42B

EBITDA (TTM)

 
$658.00M

Free Cashflow (TTM)

 
$99.00M

Pricing

1D span
$59.08$60.24
52W span
$36.00$61.20

Analyst Ratings

The price target is $57.89 and the stock is covered by 9 analysts.

Buy

1

Hold

7

Sell

1

Information

Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

16,900

Biotechnology & Drugs

Health Care

Identifier

ISIN

US1488061029

Primary Ticker

CTLT

Knockouts

Join the conversation